Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 1:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 452 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Progesterone 100 MG Clear all
Not yet recruiting No phase listed Observational

An Observational Study to Learn How Mirena and Other Progestogen Treatments Are Used for Endometrial Protection in Women 40+ With a Uterus in the United States Receiving Estrogen Therapy, and Their Respective Health Outcomes

NCT07795606
View directory record Official record
Conditions
Estrogen Therapy
Interventions
Estrogen therapy, Mirena levonorgestrel-releasing intrauterine system, Other progestogen therapy
Drug · Device
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older · Female only
Enrollment
456,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Ann Arbor, Michigan • Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 30, 2026, 1:44 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

NCT06938711
View directory record Official record
Conditions
Breast Cancer
Interventions
Elacestrant, Onapristone
Drug
Lead sponsor
Context Therapeutics Inc.
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Sep 30, 2026, 1:44 PM EDT
Not yet recruiting Phase 2 Interventional

Investigating Novel Interventions for Low Back Pain in US Military Veterans: A Randomized Controlled Adaptive Phase II Trial

NCT05935761
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Pregnenolone, DHEA, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 30, 2026, 1:44 PM EDT
Completed Not applicable Interventional Results available

Progesterone for Postpartum Cocaine Relapse

NCT01249274
View directory record Official record
Conditions
Cocaine Abuse, Cocaine Dependence
Interventions
Progesterone, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 30, 2026, 1:44 PM EDT
Completed Phase 1 Interventional

Progesterone for the Treatment of COVID-19 in Hospitalized Men

NCT04365127
View directory record Official record
Conditions
COVID-19, Sars-CoV2
Interventions
Progesterone 100 MG
Drug
Lead sponsor
Sara Ghandehari
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 30, 2026, 1:44 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Vaginal Progesterone Versus Progesterone in Oil in Donor Egg Recipient In Vitro Fertilization Cycles Utilizing Vitrified Donor Eggs

NCT01465373
View directory record Official record
Conditions
Infertility
Interventions
Endometrin, Progesterone in Oil
Drug
Lead sponsor
Fertility Centers of Illinois
Other
Eligibility
21 Years to 49 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 4, 2011 · Synced Sep 30, 2026, 1:44 PM EDT
Completed No phase listed Observational

Study of Urine Samples From Women With Newly Diagnosed Breast Cancer Enrolled on Clinical Trial UNMC-08105

NCT00959244
View directory record Official record
Conditions
Breast Cancer
Interventions
high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry, medical chart review
Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Sep 30, 2026, 1:44 PM EDT
Completed Early Phase 1 Interventional Results available

The Role of Neuroactive Steroids in Stress, Drug Craving and Drug Use in Cocaine Use Disorders

NCT03953612
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Pregnenolone (PREG), Placebos
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Sep 30, 2026, 1:44 PM EDT
Completed Phase 2 Interventional Results available

Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer

NCT00232505
View directory record Official record
Conditions
Breast Cancer
Interventions
cetuximab, carboplatin
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Sep 30, 2026, 1:44 PM EDT
Completed Phase 3 Interventional Results available

Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery

NCT01004029
View directory record Official record
Conditions
Preterm Birth
Interventions
Hydroxyprogesterone Caproate Injection (HPC), 250mg/mL, Vehicle
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
41
States / cities
Montgomery, Alabama • Tucson, Arizona • La Mesa, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Sep 30, 2026, 1:44 PM EDT
Completed Phase 2 Interventional

The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers

NCT00900900
View directory record Official record
Conditions
Substance Withdrawal Syndrome
Interventions
dehydroepiandrosterone (DHEA), pregnenolone, Placebo
Dietary Supplement · Drug
Lead sponsor
Jed E. Rose
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2012 · Synced Sep 30, 2026, 1:44 PM EDT
Completed Phase 3 Interventional Results available

Progesterone vs Placebo Therapy for Women With Epilepsy

NCT00029536
View directory record Official record
Conditions
Epilepsy
Interventions
Progesterone Lozenges, Matched Placebo Lozenges
Biological · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
13 Years to 45 Years · Female only
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
14
States / cities
Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Sep 30, 2026, 1:44 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion

NCT04597099
View directory record Official record
Conditions
PCOS, Polycystic Ovary Syndrome
Interventions
Micronized progesterone, Placebo, Flutamide, Estradiol patch
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Sep 30, 2026, 1:44 PM EDT
Terminated Not applicable Interventional Results available

Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone

NCT01428193
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Hyperandrogenism
Interventions
Flutamide, Progesterone, estrace
Drug
Lead sponsor
University of Virginia
Other
Eligibility
13 Years to 17 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Sep 30, 2026, 1:44 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Perimenopausal Estrogen Replacement Therapy Study

NCT01308814
View directory record Official record
Conditions
Perimenopause, Menopause, Depression
Interventions
Estradiol, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Sep 30, 2026, 1:44 PM EDT
Completed Phase 3 Interventional Results available

S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy

NCT01385137
View directory record Official record
Conditions
Arthralgia, Breast Cancer, Pain
Interventions
omega-3 fatty acid, placebo
Dietary Supplement · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
292
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 215 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Sep 30, 2026, 1:44 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism

NCT00837616
View directory record Official record
Conditions
Turner Syndrome, Hypogonadism, Premature Ovarian Failure
Interventions
17 B estradiol orally, 17 B estradiol
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 20 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
2
States / cities
Jacksonville, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Sep 30, 2026, 1:44 PM EDT
Completed Phase 2 Interventional Results available

A Study of Pregnenolone in the Treatment of Individuals With Autism

NCT01881737
View directory record Official record
Conditions
Autistic Disorder
Interventions
Pregnenolone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Sep 30, 2026, 1:44 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Investigation of Female Reproductive Hormone Dynamics During Adolescence

NCT02486757
View directory record Official record
Conditions
Menstruation Disturbances
Interventions
micronized progesterone, transdermal estradiol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 16 Years · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 24, 2018 · Synced Sep 30, 2026, 1:44 PM EDT
Completed Not applicable Interventional Results available

Improving the Clinical Encounter to Enhance Delivery of an Individualized Prematurity Prevention Plan

NCT04149002
View directory record Official record
Conditions
Preterm Birth
Interventions
Intervention Arm Weekly IP3 text messages, Active Control Arm General pregnancy text messages
Behavioral · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Sep 30, 2026, 1:44 PM EDT
Completed Phase 2 Interventional Results available

A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)

NCT00451204
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Estriol, Placebo, Copaxone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Sep 30, 2026, 1:44 PM EDT
Completed Phase 3 Interventional

Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.

NCT04549116
View directory record Official record
Conditions
Infertility
Interventions
Progesterone-IBSA Injectable Solution, Progesterone Vaginal Gel with Applicator, Placebo Vaginal gel with applicator, Placebo injectable solution
Drug
Lead sponsor
IBSA Institut Biochimique SA
Industry
Eligibility
35 Years to 42 Years · Female only
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
24
States / cities
Tempe, Arizona • Encino, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 30, 2026, 1:44 PM EDT
Terminated Not applicable Interventional Results available

Efficacy Study of Raloxifene to Induce Ovulation in Polycystic Ovarian Syndrome

NCT01607320
View directory record Official record
Conditions
Polycystic Ovarian Syndrome
Interventions
Raloxifene, Clomiphene
Drug
Lead sponsor
Bruce Lessey
Other
Eligibility
18 Years to 36 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Sep 30, 2026, 1:44 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Continuation of Subcutaneous and Intramuscular Depot Medroxyprogesterone Acetate in Post-abortion Patients

NCT05505435
View directory record Official record
Conditions
Contraception
Interventions
Depot-Medroxyprogestereone Acetate
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 30, 2026, 1:44 PM EDT